In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteopharm

Executive Summary

Osteopharm is trying to create both therapeutics and diagnostics for osteoporosis, based on the work of its CSO, Cherk S. Tam.

You may also be interested in...



Bone-Building Start-Ups

To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.

Cosmetic Talc Stakeholders Should Be Watching US EPA Asbestos Developments In 2021

In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.

QUOTED. 28 January 2021. Andrea Riposat.

L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.

Topics

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel